JP2020530494A - 健康な腸バリアを維持及び回復するための組成物及び方法 - Google Patents

健康な腸バリアを維持及び回復するための組成物及び方法 Download PDF

Info

Publication number
JP2020530494A
JP2020530494A JP2020530424A JP2020530424A JP2020530494A JP 2020530494 A JP2020530494 A JP 2020530494A JP 2020530424 A JP2020530424 A JP 2020530424A JP 2020530424 A JP2020530424 A JP 2020530424A JP 2020530494 A JP2020530494 A JP 2020530494A
Authority
JP
Japan
Prior art keywords
bacterial
pharmaceutical composition
rrna sequence
composition according
salmonella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020530424A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019032573A5 (enExample
JP2020530494A5 (enExample
Inventor
サンティアゴ、マリーナ
ロエロフス、ケビン
Original Assignee
フィンチ セラピューティクス、インコーポレイテッド．
フィンチ セラピューティクス、インコーポレイテッド．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フィンチ セラピューティクス、インコーポレイテッド．, フィンチ セラピューティクス、インコーポレイテッド． filed Critical フィンチ セラピューティクス、インコーポレイテッド．
Publication of JP2020530494A publication Critical patent/JP2020530494A/ja
Publication of JP2020530494A5 publication Critical patent/JP2020530494A5/ja
Publication of JPWO2019032573A5 publication Critical patent/JPWO2019032573A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020530424A 2017-08-07 2018-08-07 健康な腸バリアを維持及び回復するための組成物及び方法 Pending JP2020530494A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762542035P 2017-08-07 2017-08-07
US62/542,035 2017-08-07
PCT/US2018/045593 WO2019032573A1 (en) 2017-08-07 2018-08-07 COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER

Publications (3)

Publication Number Publication Date
JP2020530494A true JP2020530494A (ja) 2020-10-22
JP2020530494A5 JP2020530494A5 (enExample) 2021-09-24
JPWO2019032573A5 JPWO2019032573A5 (enExample) 2023-05-12

Family

ID=65271741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530424A Pending JP2020530494A (ja) 2017-08-07 2018-08-07 健康な腸バリアを維持及び回復するための組成物及び方法

Country Status (8)

Country Link
US (2) US11865145B2 (enExample)
EP (1) EP3664823B1 (enExample)
JP (1) JP2020530494A (enExample)
KR (1) KR20200038506A (enExample)
CN (1) CN111328284A (enExample)
AU (1) AU2018313766A1 (enExample)
CA (1) CA3072032A1 (enExample)
WO (1) WO2019032573A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 腸内の抗生物質耐性菌を除菌するための組成物及び方法
WO2022158244A1 (ja) * 2021-01-21 2022-07-28 株式会社晩聲社 細菌叢移植用組成物、その製造方法及び移植方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
US20220054561A1 (en) * 2018-12-14 2022-02-24 The University Of North Carolina At Chapel Hill Lachnospiraceae mitigates against radiation-induced hematopoietic/gastrointestinal injury and death, and promotes cancer control by radiation
BR112022000875A2 (pt) 2019-07-19 2022-03-29 Finch Therapeutics Holdings Llc Métodos e produtos para tratamento de distúrbios gastrointestinais
US20220339212A1 (en) 2019-08-28 2022-10-27 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
EP4041264A1 (en) 2019-10-07 2022-08-17 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
KR102215596B1 (ko) * 2019-12-11 2021-02-15 주식회사 에이치이엠 신규한 스트렙토코커스 써모필러스 hem 14 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
AU2021220800A1 (en) * 2020-02-10 2022-07-07 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
KR102363098B1 (ko) * 2020-06-19 2022-02-16 한국식품연구원 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법
FR3114106B1 (fr) * 2020-09-16 2025-03-28 Lnc Therapeutics Souche bactérienne appartenant au genre Christensenella et compositions
KR102738021B1 (ko) * 2020-10-20 2024-12-05 서울대학교병원 라크노스피로세 과 균주 검출 제제를 포함하는 동물의 염증성 질환 위험도 예측 또는 진단용 조성물
MX2023006146A (es) * 2020-11-25 2023-07-31 Seres Therapeutics Inc Composiciones bacterianas diseñadas para tratar la enfermedad de injerto contra huésped.
US20240115623A1 (en) * 2020-12-23 2024-04-11 Maat Pharma Method of expanding a complex community of microorganisms
CA3214687A1 (en) * 2021-04-06 2022-10-13 Quansheng LIN Bacterial strain, composition, drug for use in combination and use
WO2023225573A2 (en) * 2022-05-17 2023-11-23 Purdue Research Foundation Assays, kits and methods for detection of contamination
CN114933998B (zh) * 2022-06-14 2023-07-07 善恩康生物科技（苏州）有限公司 能够改善衰老状态或提升运动能力的德氏乳杆菌保加利亚亚种菌株及其应用
KR102626402B1 (ko) * 2022-08-31 2024-01-19 주식회사 바이오뱅크힐링 크리스텐세넬라 미누타 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2024049207A1 (ko) * 2022-08-31 2024-03-07 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN118384188B (zh) * 2023-05-09 2024-11-22 广州百芮医疗科技有限公司 用于改善慢性肾脏病的乳酸菌菌株组成物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507481A (ja) * 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
JP2015520176A (ja) * 2012-06-06 2015-07-16 シャンハイ ジャオ トン ユニバーシティ 腸内細菌叢集団を改善する方法および組成物
JP2016155880A (ja) * 2005-06-17 2016-09-01 ウィスコンシン アラムニ リサーチ ファンデーション 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法
WO2017091783A2 (en) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Designed bacterial compositions
JP2017514872A (ja) * 2014-05-02 2017-06-08 アトランティック ファーマシューティカルズ（ホールディングス）リミテッド 消化管における放射線誘発性疾患のアンチセンス治療

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US891777A (en) 1907-03-05 1908-06-23 Walter Langstroth Drafting instrument.
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
NL294835A (enExample) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (enExample) 1965-10-01 1967-11-13
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (enExample) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
IT1102524B (it) 1977-03-29 1985-10-07 Capsugel Ag Capsula di contenimento per materiali viscosi in particolare un preparato farmaceutico liquido e procedimento per la sua produzione
DE2722806C2 (de) 1977-05-20 1984-12-13 Capsugel AG, Basel Kapselkörper für eine Steckkapsel für Arzneimittel oder andere portionsweise zu verpackende Stoffe, sowie Verfahren zu seiner Herstellung
DE2722807A1 (de) 1977-05-20 1978-11-23 Capsugel Ag Verfahren zum herstellen einer mit viskosem stoff gefuellten steckkapsel
DE2722822C2 (de) 1977-05-20 1984-11-08 Capsugel AG, Basel Verfahren zum Herstellen einer zum Aufnehmen eines viskosen Stoffes, insbesondere eines flüssigen Arzneimittels, geeigneten Steckkapsel
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH642990A5 (de) 1978-07-24 1984-05-15 Parke Davis & Co Verfahren zum faerben von gelatine fuer kapseln mit hilfe eines gegen den abbau durch licht oder oxidation stabilisierten natuerlichen farbstoffes.
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
EP0303246A3 (en) 1987-08-12 1990-06-20 The B.F. Goodrich Company Hydrogenated, ring-opened polymers of cycloolefins
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
US5317849A (en) 1992-08-07 1994-06-07 Sauter Manufacturing Corporation Encapsulation equipment and method
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
DK0760848T3 (da) 1994-05-26 1998-09-23 Bracco Spa Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1998013068A1 (fr) 1996-09-26 1998-04-02 Vladimir Borisovich Kuperman Medicament prophylactique 'trisan'
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
EP1077252A1 (en) 1998-05-06 2001-02-21 Keijiro Nakamura Microbial culture liquors containing microorganisms differing in characteristics and living in symbiosis and metabolites thereof, carriers and adsorbents containing the active components of the culture liquors and utilization of the same
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
FR2779962B1 (fr) 1998-06-17 2002-12-06 Karim Ioualalen Composition cosmetique ou dermopharmaceutique sous forme de perles et procedes pour la preparation
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
HUP0103502A2 (hu) 1998-09-17 2002-01-28 Baxter Healthcare S.A. Streptococcus Cbéta-fehérje készítmények
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
ID30071A (id) 1998-12-11 2001-11-01 Urex Biotech Inc Pemberian oral lactobacillus untuk pengobatan dan pencegahan infeksi urogental
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7763276B1 (en) 1999-02-26 2010-07-27 Shionogi & Co., Ltd. Chewable soft capsules having improved administration properties and process for producing the same
HK1047537A1 (zh) 1999-07-30 2003-02-28 Smithkline Beecham Plc 多元藥物劑型
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
PE20030284A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0122935D0 (en) 2001-09-24 2001-11-14 Meridica Ltd Dispensing small quantities of particles
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
PT1492505E (pt) 2002-04-05 2015-10-06 Euro Celtique Sa Preparação farmacêutica contendo oxicodona e naloxona
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
EP1396263A1 (en) 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
JP2007518693A (ja) 2003-08-18 2007-07-12 ザ バイオ バランス コーポレイション 安定な液体プロバイオティクス組成物、その調製および適用
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
NZ550501A (en) * 2004-04-13 2009-06-26 Meiji Dairies Corp Use of a fermentation product of propionic acid bacterium for treating inflammatory bowel diseases
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
GB0414811D0 (en) 2004-07-01 2004-08-04 Meridica Ltd Dispensing small quantities of particles
JP2006018748A (ja) 2004-07-05 2006-01-19 Canon Inc 情報処理装置及びその制御方法、並びにコンピュータプログラム及びコンピュータ可読記憶媒体
ATE367821T1 (de) 2004-08-05 2007-08-15 Anidral Srl Folsäure produzierende bifidobacterium bakterienstämme, ihre formulierungen und verwendung
US8168171B2 (en) 2004-08-05 2012-05-01 Probiotical S.P.A. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20070254314A1 (en) 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
CA2581775A1 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
US7799328B2 (en) 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
JP4933538B2 (ja) 2005-05-20 2012-05-16 ダウ グローバル テクノロジーズ エルエルシー 無線周波識別標識を用いた経口薬服薬履行監視
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7845475B2 (en) 2006-05-19 2010-12-07 Her Yuan Chyun Co., Ltd. Controller for magnetic wheels
EP1886784A1 (en) 2006-08-09 2008-02-13 Pfizer Products Inc. Clamping apparatus and method
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
ES2895666T3 (es) 2006-10-27 2022-02-22 Capsugel Belgium Nv Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
EP2136825B1 (en) 2007-03-01 2013-11-20 Probi Ab Use of lactobacillus plantarum for increasing bacterial diversity
MX2009010419A (es) 2007-03-28 2010-02-18 Alimentary Health Ltd Cepas de bacterias bifidas probioticas.
US8709398B2 (en) 2007-03-28 2014-04-29 Alimentary Health Limited Probiotic Bifidobacterium strains
WO2008122966A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
CA2942083C (en) 2007-04-26 2019-01-29 Sigmoid Pharma Limited Manufacture of multiple minicapsules
AU2007352872B2 (en) 2007-05-07 2013-03-14 Evonik Operations Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN101686931B (zh) 2007-06-06 2013-06-19 巴斯夫欧洲公司 用于制备可咀嚼片剂和锭剂的药物配制剂
WO2008148742A2 (de) 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
RU2479587C2 (ru) 2007-07-27 2013-04-20 Карджилл, Инкорпорейтед Микронизация полиолов
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009032560A1 (en) 2007-08-31 2009-03-12 Invista Technologies S.Ar.L. Oxygen scavenging plastic compositions
WO2009041651A1 (ja) 2007-09-27 2009-04-02 Mitsubishi Tanabe Pharma Corporation 速崩壊性固形製剤
BRPI0817927A2 (pt) 2007-10-01 2015-04-07 Lesvi Laboratorios Sl Comprimidos orodispersiveis
EP2214635A1 (en) 2007-10-19 2010-08-11 Purdue Research Foundation Solid formulations of crystalline compounds
ES2431572T3 (es) 2007-10-20 2013-11-27 Université de Liège Especies bifidobacterianas
CA2740434C (en) 2007-10-26 2017-11-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
EP2233129B1 (en) 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
CN101496819A (zh) 2008-01-31 2009-08-05 青岛东海药业有限公司 真杆菌、梭菌制剂及其应用
KR100913405B1 (ko) 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
WO2010036876A2 (en) * 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
HRP20240317T1 (hr) 2008-10-02 2024-06-07 Salix Pharmaceuticals, Ltd. Liječenje hepatičke encefalopatije uporabom rifaksimina
TW201018819A (en) 2008-10-02 2010-05-16 Pfizer Rotary supply joint, rotary timing valve and product handling apparatus
EP2358328B1 (en) 2008-11-20 2013-04-10 Capsugel Belgium NV Apparatus for handling capsules and capsule processing equipment including such an apparatus
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
DK2424972T3 (da) 2009-04-30 2013-10-14 Actogenix Nv Kryobeskyttende midler til frysetørring af mælkesyrebakterier
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
US20120064133A1 (en) 2009-05-28 2012-03-15 Ishwar Chauhan Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
BR112012006651B1 (pt) 2009-09-24 2021-11-03 Capsugel Belgium Nv Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
EP3260126A1 (en) 2009-10-09 2017-12-27 Prothera, Inc. Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2011058536A1 (en) 2009-11-11 2011-05-19 Alimentary Health Limited A bifidobacterium strain
US8810259B2 (en) 2009-11-13 2014-08-19 Capsugel Belgium Nv Method of inspection of sealed capsules with a process of determination of the quality of the seal and related equipment for in-line inspection
PT2523661T (pt) 2010-01-15 2017-06-21 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Inibidores de nkcc para o tratamento de autismo
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
HRP20220751T1 (hr) 2010-02-01 2022-09-02 Rebiotix, Inc. Bakterioterapija clostridium difficile kolitisa
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
AU2011226324B2 (en) 2010-03-10 2015-09-24 Nogra Pharma Limited Compositions for colon lavage and methods of making and using same
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
US20120020941A1 (en) 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
NZ607043A (en) 2010-08-04 2015-05-29 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
AU2011313763A1 (en) 2010-10-04 2013-05-30 Emma Allen-Vercoe Detection of Fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
SMT201800226T1 (it) 2010-10-07 2018-07-17 California Inst Of Techn Trattamento probiotico contro l'autismo
ES2797348T3 (es) 2010-10-08 2020-12-02 Capsugel Belgium Nv Aparato y procedimiento para adquirir una imagen bidimensional de la superficie de un objeto tridimensional
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP5860480B2 (ja) 2011-01-11 2016-02-16 キャプシュゲル・ベルジウム・エヌ・ヴィ プルランを含む新しい硬カプセル
US10940169B2 (en) * 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
WO2012122274A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Self-emulsifying formulations and methods of use thereof
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
WO2014152484A1 (en) 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US20140227357A1 (en) 2011-09-14 2014-08-14 Capsugel Belgium Nv Fill formulations and capsules and method of use to avoid migration of fill into or through the shell
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
WO2013053836A1 (en) * 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprising anaerobically cultivated human intestinal microbiota
GB201118232D0 (en) 2011-10-21 2011-12-07 M W Encap Ltd Pharmaceutical composition
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US9176026B2 (en) 2011-12-15 2015-11-03 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
EP2769218B1 (en) 2012-05-02 2016-08-10 Charles River Laboratories, Inc. Viability staining method
EP3446713A3 (en) 2012-05-02 2019-05-15 Capsugel Belgium NV Aqueous dispersions of controlled release polymers and shells and capsules thereof
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US10220089B2 (en) 2012-08-29 2019-03-05 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
JP2015535280A (ja) 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン 胃腸管において有益な細菌を刺激する方法及び組成物
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
BR112015012123A8 (pt) 2012-11-26 2018-01-23 Borody Thomas J composições para a recuperação de uma microbiota fecal e métodos para produzir e usar as mesmas.
CA2899926C (en) 2013-02-04 2025-11-18 Seres Therapeutics, Inc. DIGESTIVE TUBE FILLING COMPOSITIONS
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
CA3013541C (en) 2013-03-14 2021-01-19 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN105307654B (zh) 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 用于治疗微生物区系相关的精神病况和疾病的组合物和方法
JP2016521284A (ja) * 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
HRP20181302T1 (hr) 2013-06-05 2018-11-02 Rebiotix, Inc. Terapija za obnavljanje mikrobiota (mrt), pripravci i postupci proizvodnje
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
JP2016530239A (ja) 2013-07-09 2016-09-29 ピュアテック ベンチャーズ、エルエルシー 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
CA2926466C (en) 2013-10-03 2021-11-16 Frederic Bushman Compositions comprising a defined microbiome and methods of use thereof
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US11213552B2 (en) * 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
EP3107553B1 (en) 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
ES2727373T3 (es) 2014-03-28 2019-10-15 Yakult Honsha Kk Bacteria productora de butirato y su uso
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
CN106573015B (zh) 2014-06-11 2021-11-26 麻省理工学院 肠溶弹性体
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
SE1550189A1 (en) 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
CN107771083A (zh) * 2015-04-23 2018-03-06 卡莱多生物科技有限公司 聚糖治疗剂和治疗方法
WO2016183577A1 (en) 2015-05-14 2016-11-17 Crestovo Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN108243608A (zh) 2015-05-22 2018-07-03 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
KR20180100543A (ko) 2015-10-26 2018-09-11 크레스토보 홀딩스 엘엘씨 대변 세균총 관련 요법을 위한 조성물 및 방법
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
CN109803534A (zh) 2016-06-01 2019-05-24 克雷斯顿沃控股公司 用于治疗炎性肠病（ibd）和其他疾病的组合物和方法
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180000872A1 (en) 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018057747A1 (en) 2016-09-21 2018-03-29 Finch Therapeutics, Inc. Pharmaceutical compositions and methods for delivering microbial compositions
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
FR3062063B1 (fr) * 2017-01-26 2019-04-19 Centre National De La Recherche Scientifique Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
SG11201913701VA (en) * 2017-07-17 2020-02-27 smartDNA Pty Ltd Method of diagnosing a dysbiosis
CN111328331A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于将肠道中的抗生素抗性细菌去定植的组合物和方法
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
WO2019032575A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. TREATMENT OF LIVER DISEASE BY MODULATION OF MICROBIOMA
WO2019075344A1 (en) 2017-10-12 2019-04-18 Crestovo Holdings Llc FECAL MICROBIOTE TRANSPLANTATION TO TREAT HEMORRHAGIC RECTOCOLITE
CN112203669A (zh) 2018-02-23 2021-01-08 克雷斯顿沃控股公司 微生物组相关的免疫疗法
US20190358274A1 (en) 2018-05-25 2019-11-28 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016155880A (ja) * 2005-06-17 2016-09-01 ウィスコンシン アラムニ リサーチ ファンデーション 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法
JP2014507481A (ja) * 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 結腸微生物相移植のための組成物及び方法
JP2015520176A (ja) * 2012-06-06 2015-07-16 シャンハイ ジャオ トン ユニバーシティ 腸内細菌叢集団を改善する方法および組成物
JP2017514872A (ja) * 2014-05-02 2017-06-08 アトランティック ファーマシューティカルズ（ホールディングス）リミテッド 消化管における放射線誘発性疾患のアンチセンス治療
WO2017091783A2 (en) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Designed bacterial compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVIS,C.L. ET AL.: "Database DDBJ , ACCESSION NO: JQ465929", DEFINITION:UNCULTURED BACTERIUM CLONE 070047_240 16S RIBOSOMAL RNA GENE,PARTIAL SEQUENCE., vol. Submitted (09-JAN-2012), JPN6023003188, pages Direct Submission, ISSN: 0004977571 *
EMBO MOLECULAR MEDICINE, vol. 9(4), JPN6022020967, February 2017 (2017-02-01), pages 448 - 461, ISSN: 0005098564 *
PLOS ONE, vol. 10(9), JPN6022020960, 2015, pages 0138746 - 1, ISSN: 0004787229 *
日消誌, vol. 112, JPN6022020959, 2015, pages 1973 - 1981, ISSN: 0004977570 *
領域融合レビュー, vol. 5, JPN6022020963, 2016, pages 007 - 1, ISSN: 0005098565 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 腸内の抗生物質耐性菌を除菌するための組成物及び方法
WO2022158244A1 (ja) * 2021-01-21 2022-07-28 株式会社晩聲社 細菌叢移植用組成物、その製造方法及び移植方法

Also Published As

Publication number Publication date
KR20200038506A (ko) 2020-04-13
US11865145B2 (en) 2024-01-09
EP3664823A4 (en) 2021-05-12
CN111328284A (zh) 2020-06-23
AU2018313766A1 (en) 2020-02-20
CA3072032A1 (en) 2019-02-14
EP3664823B1 (en) 2024-06-05
EP3664823A1 (en) 2020-06-17
US20200368295A1 (en) 2020-11-26
US20240033305A1 (en) 2024-02-01
WO2019032573A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
US20240033305A1 (en) Compositions and methods for maintaining and restoring a healthy gut barrier
US20240307460A1 (en) Compositions and methods for decolonizing antibiotic-resistant bacteria in the gut
US12350298B2 (en) Microbiome related immunotherapies
US12290538B2 (en) Methods and products for treatment of gastrointestinal disorders
US20220257670A1 (en) Methods and products for treatment of gastrointestinal disorders
US20240263251A1 (en) Compositions and methods for providing secondary bile acids to a subject
US20240226187A9 (en) Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
WO2021097288A1 (en) Compositions and methods for treating neurodegenerative diseases
WO2021142353A1 (en) Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
HK40044298A (en) Microbiome related immunotherapies
WO2021142347A1 (en) Compositions and methods for non-alcoholic steatohepatitis (nash)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704